Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/17/2005CA2564886A1 Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, increasing nutrient delivery and/or promoting increased vascular response in an individual
11/17/2005CA2564866A1 Solid dosage form of wetted heparin
11/17/2005CA2564750A1 Controlled release metformin compositions
11/17/2005CA2564634A1 Permeation enhancing compositions for anticholinergic agents
11/17/2005CA2564394A1 Method for the treatment of back pain
11/17/2005CA2564326A1 Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite
11/17/2005CA2564264A1 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
11/17/2005CA2564099A1 Alcohol metabolism accelerating composition, and food or drink containing the composition
11/17/2005CA2564068A1 Use of (4-alkylpiperazinyl) (phenyl) methanones in the treatment of alzheimer's disease
11/17/2005CA2564033A1 A method for the prevention of thromboembolic disorders
11/17/2005CA2564025A1 A method for the treatment or prevention of cardiac hypertrophy
11/17/2005CA2564009A1 Piperazine derivatives of alkyl oxindoles
11/17/2005CA2564005A1 Radiopharmaceutical and methods of synthesis and use thereof
11/17/2005CA2563955A1 Novel biaromatic compounds which activate ppar.gamma.-type receptors, their process of preparation and their usein cosmetic or pharmaceutical compositions
11/17/2005CA2563681A1 Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
11/17/2005CA2563521A1 Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
11/17/2005CA2563400A1 Medicament for the treatment of fungal infections, particularly aspergillosis
11/17/2005CA2563086A1 Naltrexone long acting formulations and methods of use
11/17/2005CA2562864A1 Dealkylated derivatives of pyrrolo[2,1-b]benzothiazepines with atypical antipsychotic activity
11/17/2005CA2562750A1 Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
11/17/2005CA2562561A1 6-substituted pyridoindolone derivatives production and therapeutic use thereof
11/17/2005CA2562287A1 Sustained-release oral molsidomine composition for treating atherosclerosis
11/17/2005CA2561141A1 Methods for treating blood disorders with nitric oxide donor compounds
11/17/2005CA2560865A1 Cancer associated antigens
11/17/2005CA2560387A1 Cytokine inhibitors
11/17/2005CA2558113A1 Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds
11/16/2005EP1596445A1 Process for doping organic semiconductors with derivatives of diiminoquinones
11/16/2005EP1595954A1 Human papilloma virus inhibition by antisense oligonucleotides
11/16/2005EP1595884A2 Salt of sulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations
11/16/2005EP1595881A1 Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
11/16/2005EP1595879A2 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
11/16/2005EP1595878A1 Indole derivatives with apoptosis inducing activity
11/16/2005EP1595871A2 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
11/16/2005EP1595867A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
11/16/2005EP1595573A2 Stent comprising manipulators of nitrosative stress to reduce restenosis
11/16/2005EP1595545A1 Blood-vessel-growth promoter
11/16/2005EP1595544A1 Remedy for diabetes
11/16/2005EP1595543A2 Antineoplastic pharmaceutical compositions comprising taurolidine or taurultam and 5-fluorouracil
11/16/2005EP1595542A1 Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
11/16/2005EP1595541A1 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
11/16/2005EP1595540A1 Composition containing an angiotensin II receptor antagonist and a diuretic and its use for the treatment of hypertension
11/16/2005EP1595539A1 Drug for reducing side effects in ribavirin interferon combination therapy
11/16/2005EP1595538A2 Modified release tamsulosin tablets
11/16/2005EP1595537A1 Buccal cavity treatment composition and corresponding uses thereof
11/16/2005EP1595536A1 Pharmaceuticals comprising shikonins as active constituent
11/16/2005EP1595531A1 Stable pharmaceutical solution formulations for pressurized metered dose inhalers
11/16/2005EP1595129A2 Methods of identifying modulators of cellular glycosylation using gtrap3-18
11/16/2005EP1594983A2 Use of a novel polymorphism in the hsgk1 gene in the diagnosis of hypertonia and use of the sgk gene family in the diagnosis and therapy of the long qt syndrome
11/16/2005EP1594976A2 ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ACTIVITY AGAINST RESISTANT HIV STRAINS
11/16/2005EP1594959A2 Novel therapeutic method and compositions for topical administration
11/16/2005EP1594897A2 Use of il-6 antagonists in combination with steroids to enhance apoptosis
11/16/2005EP1594889A2 Nell peptide expression systems and bone formation activity of nell peptide
11/16/2005EP1594888A2 Tolerance-induced targeted antibody production
11/16/2005EP1594886A1 Antitumoral d-homoestra-1, 3, 5 (10)-trien-3-yl 2-substituted sulfamates
11/16/2005EP1594885A1 Medicament for inhibiting tumour growth
11/16/2005EP1594884A1 Antitumoral 18a-homoestra-1,3,5(10)-trien-3-yl 2-substituted sulfamates
11/16/2005EP1594875A1 Porphyrin derivatives
11/16/2005EP1594872A1 Cannabinoid receptor ligands and uses thereof
11/16/2005EP1594870A1 Substituted indolepyridinium as anti-infective compounds
11/16/2005EP1594866A1 Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives
11/16/2005EP1594865A2 Antibacterial agents
11/16/2005EP1594861A1 Triazole compounds and the therapeutic use thereof
11/16/2005EP1594860A2 Library of biphenyl derivatives useful for identifying compounds having both beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
11/16/2005EP1594857A2 N-monoacylated o-phenylenediamines as anti-cancer agents
11/16/2005EP1594856A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain
11/16/2005EP1594854A2 Thiazolyl-based compounds useful as kinase inhibitors
11/16/2005EP1594849A2 Compounds, compositions, and methods
11/16/2005EP1594847A2 Substituted azole derivatives as therapeutic agents
11/16/2005EP1594846A1 Bis(hetero)aryl carboxamide derivatives for use as pgi2 antagonists
11/16/2005EP1594845A2 Benzene acetamide compounds useful as serine protease inhibitors
11/16/2005EP1594841A1 Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
11/16/2005EP1594840A1 Piperidine-benzenesulfonamide derivatives
11/16/2005EP1594836A1 Hydroxy-tetrahydro-naphthalenylurea derivatives
11/16/2005EP1594830A1 Depigmentation agents
11/16/2005EP1594762A1 Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
11/16/2005EP1594575A2 Modulation of atp production or content in the hypothalamus
11/16/2005EP1594574A2 Nk1 receptor antagonists for the treatment of functional dyspepsia
11/16/2005EP1594566A2 Implantable method to regulate blood pressure by means of coded nerve signals
11/16/2005EP1594560A2 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
11/16/2005EP1594552A2 Topical delivery of cosmetic agents
11/16/2005EP1594544A2 Oral compositions of fenretinide having increased bioavailability and methods of using the same
11/16/2005EP1594540A1 New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies
11/16/2005EP1594531A1 Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
11/16/2005EP1594528A1 New pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins
11/16/2005EP1594524A2 Use of tryptanthrin compounds for immune potentiation
11/16/2005EP1594522A1 Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases
11/16/2005EP1594515A2 Drug formulation and delivery using crystalline methylated cyclodextrins
11/16/2005EP1594514A2 Combination therapy for treating protein deficiencies
11/16/2005EP1594513A2 Carbohydrate conjugates to prevent abuse of controlled substances
11/16/2005EP1594512A2 Compounds for the treatment of viral infection
11/16/2005EP1594511A2 Formulations of glucocorticoids to treat pathologic ocular angiogenesis
11/16/2005EP1594510A2 Method and kit for reducing the symptoms of peripheral vascular disease
11/16/2005EP1594509A2 Compositions and methods for treatment of irritable bowel syndrome and nonulcer dyspepsia
11/16/2005EP1594508A2 Novel bicyclic compounds and compositions
11/16/2005EP1594507A2 Novel antiherpes drug combinations
11/16/2005EP1594505A2 Phenylglycine derivatives useful as serine protease inhibitors
11/16/2005EP1594504A2 Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis
11/16/2005EP1594503A2 Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
11/16/2005EP1594502A1 4- (2,4-dichloro-5-methoxyphenyl)amino -6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
11/16/2005EP1594501A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
1 ... 4467 4468 4469 4470 4471 4472 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 4486 4487 ... 7860